News
-
-
-
-
PRESS RELEASE
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar
Sandoz reaches agreement with Regeneron on patent litigation related to US aflibercept biosimilar, enabling launch of Enzeevu™ by end of 2026. Agreement strengthens Sandoz biosimilar portfolio and expands US market growth strategy -
-